Full Papers
Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study
K.E. Clark1, L.M. Clayton2, R.G. Thomas3, S.G. Kelly4, L. Walker5, A.S. Herrey6, A. Dougan7, R.S. Patel8, S. Fhadil9, T.O. Millner10, S. Marino11, A. Radunovic12
- Department of Rheumatology, Barts Health NHS Trust, London, UK. kristina.clark@nhs.net
- Department of Neurology, Barts Health NHS Trust, London, UK.
- Department of Rheumatology, Barts Health NHS Trust, London, UK.
- Department of Rheumatology, Barts Health NHS Trust, London, UK.
- Department of Immunology, Barts Health NHS Trust, London, UK.
- Department of Cardiology, Barts Health NHS Trust, London, UK.
- Department of Neurology, Barts Health NHS Trust, London, UK.
- Department of Immunology, Barts Health NHS Trust, London, UK.
- Department of Cardiology, Barts Health NHS Trust, London, UK.
- Department of Neuropathology, Barts Health NHS Trust, London, UK.
- Department of Neuropathology, Barts Health NHS Trust, London, UK.
- Department of Neurology, Barts Health NHS Trust, London, UK.
CER18745
Full Papers
Free to view
(click on article PDF icon to read the article)
Received: 21/03/2025
Accepted : 15/07/2025
In Press: 03/12/2025
Abstract
OBJECTIVES:
To characterise and compare the clinical phenotypes, malignancy risk, and long-term outcomes of anti-SRP and anti-HMGCR immune-mediated necrotising myopathy (IMNM). Given the rarity of this condition, we aimed to validate established findings within our large, ethnically diverse cohort managed over a 13-year period.
METHODS:
We conducted a retrospective, observational single-centre study of all patients with anti-SRP or anti-HMGCR positive myopathy managed at our tertiary neuromuscular centre between 2010-2023.
RESULTS:
We included 57 patients (15 anti-SRP, 42 anti-HMGCR). The anti-SRP cohort was younger at disease onset (median 53 vs. 66.5 years, p<0.001) and had a higher frequency of extra-muscular features, including interstitial lung disease (26.7% vs. 2.4%) and arthritis (33.7% vs. 0%). The overall malignancy incidence was 12.3% and was low in both subgroups. In the anti-HMGCR cohort, antibody titres showed a significant positive correlation with creatine kinase (CK) (r=0.692, p<0.001) and troponin T levels (r=0.476, p=0.014). A greater proportion of anti-HMGCR patients achieved treatment-free remission compared to anti-SRP patients (21.4% vs. 13.0%).
CONCLUSIONS:
Our findings are in line with previous reporting, demonstrating that the majority of patients respond to immunosuppressive therapy, and the association of anti-SRP myopathy with more prominent systemic involvement. Anti-HMGCR antibody titres are a potentially valuable biomarker for disease activity and may have utility in guiding immunosuppression withdrawal.
